Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415 shares of common stock, which includes 1,756,097 shares of common stock sold pursuant to the exercise of the underwriters’ over-allotment option. Total gross proceeds from the offering are approximately $552 million.

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer.  

The Davis Polk capital markets team included partner Alan F. Denenberg, associate Rohit M. Malhotra and former associate Trang (Mae) Nguyen. Partner Frank J. Azzopardi and associate Katharine Jan provided intellectual property advice. The tax team included partner Michael Mollerus and associate Catherine L. Chu. Members of the Davis Polk team are based in the Northern California and New York offices.   

Copy link to share post